← Medtronic overview

Medtronic vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Medtronic PLC (MDT)

Q3 2026
▲3▼1

Medtronic Q3: Upgrades, Strong Sales, New Products, But Recalls and Tariffs Linger

  • UBS Upgrade and Strong Q1 Results UBS upgraded Medtronic to Buy, and Q1 revenue jumped 13.7% to $9.8 billion with raised guidance. Fiscal 2026 growth hit a decade-high 8.4%, showing broad business strength.

    This point highlights the positive analyst action and strong financial performance that drove the stock.

  • New Product Approvals and Acquisitions Medtronic won permanent reimbursement for renal denervation, completed the SPR Therapeutics acquisition, launched AI surgical tools, and gained FDA clearance for LigaSure on Hugo, expanding its product portfolio.

    These new products and deals are key growth drivers that can boost future revenue and investor confidence.

  • MiniMed Spin-Off Medtronic moved to spin off its diabetes unit MiniMed, a strategic move to focus on core businesses and unlock value for shareholders.

    The spin-off is a significant corporate action that could improve Medtronic's focus and valuation.

  • Recalls, Tariffs, and Lawsuits Medtronic faced a Class II Octopus 4 recall, $74 million in quarterly tariff costs (~$250 million annually), and an $88 million hernia mesh verdict with 2,400+ lawsuits pending, creating ongoing financial and reputational risks.

    These negative events weigh on the stock and represent real challenges that could pressure future earnings.

September 2026
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

Latest
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

August 2026
▲2▼2

Medtronic surges on record revenue, upgrade, and strong Q1

  • UBS upgrade and record revenue growth UBS upgraded Medtronic to Buy, citing a turnaround, and the company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion. This signals improving fundamentals and boosts investor confidence.

    This point captures the key positive developments that drove the stock during the period.

  • Strong Q1 beat and raised guidance Fiscal Q1 revenue jumped 13.7% to $9.8 billion, beating estimates, and management raised full-year guidance. Cardiac Ablation Solutions surged 88%, showing broad-based strength and supporting a higher stock price.

    This point highlights the strong quarterly performance and raised outlook that positively impacted the stock.

  • Tariff costs and hernia mesh litigation Medtronic absorbed $74 million in tariff costs, with about $250 million expected annually, pressuring margins. An $88 million hernia mesh verdict leaves over 2,400 lawsuits pending, creating legal uncertainty that could weigh on the stock.

    This point addresses the significant headwinds that partially offset the positive momentum.

  • Competitive pressure in key markets Competitive pressure in cardiovascular and diabetes, including Abbott's new device, could limit upside despite the core business growing. This competition may slow Medtronic's market share gains and cap revenue growth.

    This point highlights the competitive challenges that could restrain future performance.

▲3▼1

Medtronic beats Q1, raises guidance on heart device strength

  • Q1 beat and raised guidance Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7%, and adjusted EPS of $1.45, beating estimates. It raised full-year organic growth guidance to 7.25%-7.75% and EPS to $5.94-$6.00. This shows the business is growing faster than expected, which lifts the stock.

    This is the main new event that directly moves MDT's price.

  • Cardiac Ablation Solutions surge Cardiac Ablation Solutions grew 88% worldwide, and Cardiac Rhythm Management rose 15%. These heart-related products are driving most of the growth. Continued strength here supports the stock because it shows Medtronic is winning in a key market.

    It explains the underlying driver of the strong quarter and future growth.

  • Strategic deals and partnerships Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics, announced a partnership with Cornerstone Robotics, and invested in Pi-Cardia. These moves expand its product pipeline and technology, which can support future growth and investor confidence.

    New deals signal long-term growth potential beyond the current quarter.

  • Tariff costs and competition Medtronic expects $250 million in annual tariff costs, with $75 million hitting Q1. Also, Abbott's new diabetes device adds competition. These are real headwinds that could pressure profits and limit upside, even as the core business grows.

    It provides a fair counterweight to the positive earnings news.

▼3▲1

Medtronic's strong growth and UBS upgrade offset by tariff and legal headwinds

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic to Buy, citing a turnaround. The company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion, driven by a 78% surge in Cardiac Ablation Solutions. This positive momentum could attract more investors and push the stock higher.

    This is a new positive development that directly boosts investor confidence and the stock's outlook.

  • Tariff headwinds Medtronic absorbed a $74 million tariff impact in the latest quarter and expects roughly $250 million in fiscal 2027. These tariffs increase costs and could pressure profit margins, potentially weighing on the stock price.

    This is a new negative factor that affects future profitability and is a key concern for investors.

  • Hernia mesh lawsuit verdict A federal jury ordered Medtronic to pay $88 million in the first Covidien hernia mesh bellwether trial, with over 2,400 similar lawsuits pending. This creates legal uncertainty and potential financial liability, which could negatively impact the stock.

    This is a new legal development that introduces significant risk and could lead to further payouts.

  • Competitive pressure in cardiovascular Johnson & Johnson's MedTech cardiovascular segment grew only 3.1%, and Abiomed declined 2% amid physician caution. This suggests a challenging environment for Medtronic's cardiovascular business, potentially limiting growth.

    This is a new competitive signal that highlights potential headwinds for Medtronic's cardiovascular sales.

July 2026
▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

Q2 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

June 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

Danaher Corporation (DHR)

Q3 2026
▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

  • Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.

    The acquisition is the biggest new event and main reason for the stock's decline.

  • Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.

    This guidance cut directly impacts investor expectations and the stock's valuation.

  • Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.

    The miss highlights execution risks and weighs on sentiment.

  • Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.

    These positives show underlying business strength and innovation, providing a counterweight to the negatives.

July 2026
▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

  • Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.

    The acquisition is the biggest new event and main reason for the stock's decline.

  • Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.

    This guidance cut directly impacts investor expectations and the stock's valuation.

  • Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.

    The miss highlights execution risks and weighs on sentiment.

  • Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.

    These positives show underlying business strength and innovation, providing a counterweight to the negatives.

Latest
▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

  • Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.

    This is the main new negative event that directly answers why DHR is moving right now.

  • Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.

  • Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.

    This explains the nuance behind the revenue miss and why the stock reaction may be overdone.

  • Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.

    This provides a potential positive catalyst and shows analyst views on valuation after the decline.

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

  • Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.

    This is the main new event that caused the stock to drop over 10% this period.

  • Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.

    This explains the specific reason behind the guidance cut and the stock's decline.

  • Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.

    This is a key positive from the quarter that contrasts with the negative reaction.

  • Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.

    This provides a counterweight to the negative news and suggests the stock may rebound.

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

  • Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.

    Explains the main reason DHR is down this year and the key overhang on the stock.

  • Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.

    Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.

  • Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.

    Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.

  • Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.

    Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.

© 2026 MarketIVWhy